Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2003-02-11
2008-08-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S080000, C514S085000, C514S089000, C514S091000, C514S092000, C514S114000, C544S057000, C544S232000, C546S022000, C548S112000, C548S113000, C558S070000
Reexamination Certificate
active
07410956
ABSTRACT:
The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. This invention further relates to pharmaceutical compositions comprising these compounds, which are particularly well-suited for treatment of caspase-mediated diseases, including inflammatory and degenerative diseases. This invention further relates to methods for preparing compounds of this invention.
REFERENCES:
patent: 6184210 (2001-02-01), Keana et al.
patent: 6184244 (2001-02-01), Karanewsky et al.
patent: 6187771 (2001-02-01), Karanewsky et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 6355618 (2002-03-01), Cai et al.
patent: 2002/0169177 (2002-11-01), Kay et al.
patent: WO 94/22483 (1994-10-01), None
patent: WO 96/03982 (1996-02-01), None
patent: WO 99/02485 (1999-01-01), None
patent: WO-00/31083 (2000-06-01), None
patent: WO 00/31083 (2000-06-01), None
patent: WO 00/55114 (2000-09-01), None
patent: WO 00/55127 (2000-09-01), None
patent: WO 00/61542 (2000-10-01), None
patent: WO 01/05772 (2001-01-01), None
patent: WO 01/10383 (2001-02-01), None
patent: WO 01/16093 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/44216 (2001-06-01), None
patent: WO 01/72707 (2001-10-01), None
patent: WO 01/90070 (2001-11-01), None
patent: WO 01/94351 (2001-12-01), None
patent: WO 02/11666 (2002-02-01), None
patent: WO 02/22611 (2002-03-01), None
patent: WO 03/000173 (2003-01-01), None
Smyth, Emily, “The Trouble with Inhibitors,” Signalling Scissors, Horizon Symposia 2003, pp. 1-4.
Y. Cheng et al., “Caspase Inhibitor Affords Neuroprotection with Delayed Administration in a Rat Model of Neonatal Hypoxic-Ischemic Brain Injury.”J. Clin. Invest., 101(9), 1992-1999 (1998).
R.E. Ellis et al., “Mechanisms and Functions of Cell Death.”Annu. Rev. Cell Biol., 7, 663-698 (1991).
M. Endres et al., “Attenuation of Delayed Neuronal Death After Mild Focal Ischemia in Mice by Inhibition of the Caspase Family.”Journal of Cerebral Blood Flow and Metabolism, 18, 238-247 (1998).
P. Goldstein, “Cell Death in Us and Others.”Science, 281 (1998).
S.R. Grobmyer et al., “Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock.”Molecular Medicine, 5, 585-594 (1999).
Y.A. Lazebnik et al., “Cleavage of Poly(ADP-Ribose) Polymerase by a Proteinase with Properties Like Ice.”Nature, 371, 346-347 (1994).
J.J. Plattner and D.W. Norbeck, “Obstacles to Drug Development from Peptide Leads.” inDrug Discover Technologies, C.R. Clark and W.H. Moos, Eds., Ellis Horwood, Chichester, England, 92-126 (1990).
J.C.R. Randle et al., “ICE/Caspase-1 Inhibitors as Novel Anti-Inflammatory Drugs.”Expert Opin. Investig. Drugs, 10(7), 1-3 (2001).
S. Roggo et al., “P2/3 Oxo Azepino Indoles: A New Class of Potent Broad Spectrum Caspase Inhibitors with In Vivo Activity in the pMCAO Model.”ACS Meeting, San Diego, Apr. 2001.
I. Rodriguez et al., “Systemic Injection of a Tripeptide Inhibits the Intracellular Activation of CPP32-like Proteases In Vivo and Fully Protects Mice Against Fas-Mediated Fulminant Liver Destruction and Death.”J. Exp. Med., 184, 2067-2072 (1996).
T.V. Talanian et al., “Caspases as Targets for Anti-Inflammatory and Anti-Apoptotic Drug Discovery.”Journal of Medicinal Chemistry, 43, 3351-3371 (2000).
N.A. Thornberry, “Caspases: Key Mediators of Apoptosis.”Chemistry&Biology, 5, R97-R103 (1998).
K.P. Wilson et al., “Structure and Mechanism of Interleukin-1b Converting Enzyme.”Nature, 370, 270-275 (1994).
A.G. Yakovlev et al., “Activation of CPP32-like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury.”The Journal of Neuroscience, 17(19), 7415-7424 (1997).
H. Yaoita et al., “Attenuation of Ischemia/Reperfusion Injury in Rats by a Caspase Inhibitor.”Circulation, 97(3), 276-281 (1998).
Golec Julian M. C.
Mortimore Michael
Coppins Janet L.
Haley Jr. James F.
Horan Nina R.
Ropes & Gray LLP
Saeed Kamal A.
LandOfFree
Caspase inhibitor prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Caspase inhibitor prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase inhibitor prodrugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3998824